Live Updates on Corona Remedies IPO Allotment Status
Key Updates on Corona Remedies IPO
Corona Remedies IPO allotment status holds vital importance for investors after its initial public offering closed successfully. The IPO was subscribed 137.04 times, showing strong demand. As of now, the GMP for Corona Remedies IPO is ₹295, indicating a considerable uplift in expected listing price. All interested investors should keep track of these developments for effective portfolio strategies.
Subscription Details
- Qualified Institutional Buyers (QIBs): 278.52 times subscribed
- Non-Institutional Investors (NIIs): 208.88 times subscribed
- Retail Individual Investors (RIIs): 28.73 times subscribed
About Corona Remedies
Headquartered in Ahmedabad, Corona Remedies specializes in pharmaceutical formulations across various therapeutic areas, including women’s healthcare and cardio-diabetes. Their portfolio boasts a diverse array of 67 brands.
Investors should stay updated about the allotment process and the GMP developments as they could significantly affect trading outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.